Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2026)

PROCEPT BioRobotics has reported Cash & Equivalents over the past 7 years, most recently at $245.6 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 22.32% to $245.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $245.6 million through Mar 2026, down 22.32% year-over-year, with the annual reading at $286.5 million for FY2025, 14.15% down from the prior year.
  • Cash & Equivalents was $245.6 million for Q1 2026 at PROCEPT BioRobotics, down from $286.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $333.7 million in Q4 2024 and troughed at $149.7 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $257.2 million (2023), against an average of $253.9 million.
  • Year-over-year, Cash & Equivalents surged 230.11% in 2022 and then plummeted 44.52% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $221.9 million in 2022, then increased by 15.94% to $257.2 million in 2023, then increased by 29.74% to $333.7 million in 2024, then decreased by 14.15% to $286.5 million in 2025, then decreased by 14.26% to $245.6 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Cash & Equivalents are $245.6 million (Q1 2026), $286.5 million (Q4 2025), and $294.3 million (Q3 2025).